The Zacks Analyst Blog Highlights: Regeneron, Gilead, Medicines Co., AbbVie and Cadence - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

The Zacks Analyst Blog Highlights: Regeneron, Gilead, Medicines Co., AbbVie and Cadence

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, Feb. 20, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Regeneron (Nasdaq:REGN-Free Report), Gilead (Nasdaq:GILD-Free Report), Medicines Co. (Nasdaq:MDCO-Free Report), AbbVie (NYSE:ABBV-Free Report) and Cadence (Nasdaq:CADX-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Last week's biotech highlights include strong results from Regeneron (Nasdaq:REGN-Free Report) and Gilead's (Nasdaq:GILD-Free Report) marketing application for its next hepatitis C virus (HCV) treatment. The Medicines Co. (Nasdaq:MDCO-Free Report) was also in the news with the FDA's advisory panel refusing to back the company's antiplatelet agent, Cangrelor.

Regeneron on a Roll: There is no stopping Regeneron which continues to impress with its performance. The company's fourth quarter results were strong and guidance encouraging. Eye drug, Eylea, remains poised for growth. An FDA decision regarding the diabetic macular edema indication should be out in August.

Regeneron expects to file for a fourth indication, macular edema following branch retinal vein occlusion, shortly. The company will also be moving to a tax-efficient operating model -- the benefits should materialize from 2017. There is definitely a lot to like about Regeneron.

GILD Already Planning for Next HCV Drug: Gilead is looking to get its once-daily fixed-dose HCV cocktail treatment -- ledipasvir (NS5A inhibitor) plus Sovaldi (nucleotide analog polymerase inhibitor) -- approved in the U.S. Approval would make this combination the first oral treatment for HCV patients with genotype 1 infection to be available in the U.S. The important thing is that patients would not need to take interferon or ribavirin (RBV), which are usually associated with greater side effects.

But competition is not far behind. AbbVie (NYSE:ABBV-Free Report) recently provided data from four additional studies that evaluated its all-oral, interferon-free therapy with/without RBV in the same patient population.

AbbVie remains on track to file for its HCV treatment early in the second quarter of 2014 and expects to gain approval this year.

Both treatments look effective with high cure rates. But Gilead's treatment is once daily while AbbVie's will require more frequent dosing. However, eventually pricing will play a role as well in share uptake.

Cadence (Nasdaq:CADX-Free Report) to Be Acquired: Mallinckrodt plc will be acquiring Cadence for $14.00 per share in cash or about $1.3 billion. The offer price represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence. The acquisition is slated to go through in mid-to-late March. Cadence shares were up 26.5% on the news.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on REGN - FREE

Get the full Report on GILD - FREE

Get the full Report on MDCO - FREE

Get the full Report on ABBV - FREE

Get the full Report on CADX - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.